# Novonesis

Novonesis is a Corporate Investor based in Lyngby, Denmark.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Lyngby, Denmark
- **Region:** Europe
- **Address:** Biologiens Vej 2, 2800 Lyngby, Denmark
- **Founded:** 2024
- **Assets under management:** Undisclosed
- **Website:** www.novozymes.com
- **LinkedIn:** https://www.linkedin.com/company/novozymes

## Regulatory record

- **Reports private funds:** No

## About

Novonesis is a leading global biosolutions company formed through a combination of Chr. Hansen and Novozymes.

## Sectors

- AgriTech & FoodTech
- Healthcare Services
- Energy Transition & Renewables
- Industrial Tech

## Offices

- Franklinton, North Carolina, USA
- Salem, Virginia, USA
- Araucária, Paraná, Brazil
- Bangalore, Karnataka, India

## People

- Ester Baiget — President and CEO

## Questions

### Who runs investment decisions at Novonesis, and what is its corporate structure?

Novonesis is an operating company whose capital allocation is directed by the executive leadership team under CEO Ester Baiget, rather than through a separate investment office. The firm is majority-owned by Novo Holdings A/S, the investment arm of the Novo Nordisk Foundation, which provides governance oversight. Investment decisions are embedded in the company's operational strategy, which prioritizes in-house innovation and manufacturing expansion over third-party fund commitments.

### How does Novonesis source and develop its biosolutions?

Novonesis sources intellectual property primarily through internal R&D conducted at its Danish innovation campuses and satellite centers in India and the United States. Its innovation model relies on studying naturally occurring microbes and enzymes, then engineering them for specific uses in over 30 industries. This approach is supplemented by targeted acquisitions, such as the purchase of dsm-firmenich's animal feed enzyme business in 2025.

### Does Novonesis participate in fund commitments or only direct corporate transactions?

Novonesis operates through direct corporate transaction structures, including internal R&D allocations and specific acquisitions. The firm does not maintain a traditional corporate venture capital fund or invest as a limited partner in external venture or growth funds. Its business partnerships, including the long-running Feed Enzyme Alliance with dsm-firmenich, represent operational joint ventures rather than financial investment vehicles.

### What investment stages and sectors does Novonesis typically target?

Novonesis targets the full value chain in industrial biosolutions, from late-stage research and development through to scaled manufacturing. It focuses on the food and beverage, human health, and planetary health sectors. This translates into enzyme engineering for agricultural yields, probiotic strain development for consumer health, and industrial process optimization for manufacturing partners.

### How is Novonesis related to the Novo Nordisk Foundation and Novo Holdings?

Novonesis is majority-owned by Novo Holdings A/S, the holding and investment company responsible for managing the assets of the Novo Nordisk Foundation. This structure effectively places Novonesis under a self-governing foundation that channels dividends into scientific research and philanthropic grants, creating a stable long-term ownership model distinct from publicly-traded peers or privately-equity-backed companies.

### What is Novonesis' known posture on supply chain and operational sustainability targets?

The firm has set public targets to reduce operational emissions by 75% and supply chain emissions by 35%, using a 2018 baseline. For its 2030 strategy period, it also targets a minimum of 40% representation of the underrepresented gender in senior leadership positions. These targets appear alongside financial objectives and are reported through the company's regular investor and sustainability communications.

## Related profiles

- [Novo Tellus Capital Partners](https://altss.com/profile/novo-tellus-capital-partners)
- [Novum Capital](https://altss.com/profile/novum-capital)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/novozymes

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology